Life Bio is launching its first partial epigenetic reprogramming trial focused on glaucoma and NAION. With Michael Ringel as COO, the company transitions from promising nonhuman primate studies to human trials, offering actionable insights for longevity biotech progress.
We’re Evolving—Immortality.global 2.0 is Incubating
The platform is in maintenance while we finalize a release that blends AI and longevity science like never before.
